SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is surging, nearing a $5 trillion market cap, driven by announcements around new AI deals and partnerships with companies like Palantir and Uber. Community chatter revolves around the potential impact of these partnerships and the possibility of a deal with China, with some analysts suggesting significant upside. Some investors remain cautious, pointing to concerns about valuation and the cyclical nature of the semiconductor industry.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending due to a rejected acquisition offer for Larvotto Resources, leading to community discussion about the company's next steps and valuation; Some traders speculate on a hostile takeover. Despite this setback, UAMY's existing government contracts and position as a domestic antimony producer remain key talking points, with some viewing the dip as a buying opportunity.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending after news of Nvidia's significant equity investment and partnership to advance AI-driven 5G and 6G technology, with the community speculating on price targets and potential long-term impact. Discussions also involve the broader implications for AI in telecommunications and Nokia's role in the evolving tech landscape. Some traders are also noting the high trading volume and potential short squeeze.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amid discussions of its AI capabilities, particularly following news of a partnership with Nvidia that is expected to drive significant revenue. The collaboration focuses on integrating Nvidia's chips and software into Palantir's platforms to enhance decision-making in logistics and supply chain management, sparking bullish sentiment and speculation about Palantir's potential market cap growth.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as investors gear up for the company's earnings report, anticipating discussion of AI and cloud growth. Community members are closely watching technical indicators and discussing potential price movements.  Speculation around the impact of the OpenAI partnership and the potential for a stock split are also fueling interest.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is trending following a substantial after-hours surge driven by record Q3 revenue and a significant partnership with Brookfield to supply AI data centers with clean energy. Community discussions revolve around the potential for continued growth, the company's valuation, and the possibility of a short squeeze given the high short interest. Bloom Energy's role in providing alternative energy solutions for data centers is also a key talking point, especially with the increasing demand from AI operations.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is trending amid discussions about Gravity SUV deliveries, new partnerships, and concerns over potential dilution. Community members are weighing the company's growth prospects against its cash burn rate and production targets. Recent collaborations and expansion plans are also being actively discussed.

Another token of MartyrFi narrative to remember Tyke the Elephant. She was a female African bush elephant captured as a baby and shipped to the United States, where She was brutalised and instilled fear upon during the training for the circus, and shot 87 times whilst on the streets of Honolulu, Hawaii. She died of her injuries. She was forgotten but she will have a special place in our hearts forever  The token is built to remember and honour Tyke the elephant. The project is also built around being charitable towards elephants who may go through the same sort of abuse.

Tyke The Elephant

Tyke The Elephant ($TYKE) is gaining attention, particularly for its association with Phantom Wallet. The community is using bullish language like "moonshot" and "rocket" while emphasizing early entry and strong breakout potential. The coin's connection to popular cryptocurrencies like Bitcoin and Solana is also being highlighted.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is trending due to disappointing guidance, sparking debate about its future performance and the impact of potential tariff changes. The community is discussing whether current headwinds are temporary and represent a buying opportunity, or if deeper issues exist with the company's leadership and market position. Some traders mention potential activist investor interest, while others express concerns about the solar sector's overall prospects.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco ($CCJ) is trending as investors discuss the nuclear energy sector's potential to power AI data centers and the impact of Westinghouse's expansion plans. Community members are weighing the stock's valuation after its recent surge, considering factors like uranium supply, production targets, and analyst ratings. Some traders are taking profits, while others see pullbacks as buying opportunities, anticipating further gains driven by long-term demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MeiraGTx (MGTX) Moves 12.4% Higher: Will This Strength Last?

MeiraGTx (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of -28.05% and -0.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of UroGen Pharma gained momentum after the U.S. FDA approved Zusduri, a therapy for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer, prompting a flurry of bullish analyst revisions and heightened interest from retail investors.UroGen Pharma shares jumped 8.6% to $12.03 on Friday, hitting a three-month high, and edged up further to $12.06 in after-hours trading.Goldman SachsGoldman Sachs raised its price target to $16 from $3, noting the stock’s 22% post-approval rally surprised most investors, given the negative ODAC vote and briefing document that had flagged an unfavorable benefit-risk profile.&nbsp;In a note, analyst Paul Choi reminded investors that FDA approvals following negative oncology advisory panels are “exceedingly rare.”&nbsp;The firm remains ‘Neutral’ on the stock despite the unexpected regulatory success.OppenheimerOppenheimer raised its target to $31 from $10, reiterating an ‘Outperform’ rating and emphasizing a key update from Friday’s conference call—a $21,500 per-dose list price for Zusduri.&nbsp;Analyst Leland Gershell expects clarity on UGN-103's path to approval will help preserve franchise exclusivity beyond 2031, adding that sales could reach $1 billion over time.&nbsp;He also said he would “take advantage of any near-term weakness to buy UroGen shares.”ScotiabankScotiabank lifted its target to $47 from $23, increasing its FDA approval probability from 60% to 100%.&nbsp;The firm continues to rate the stock ‘Outperform,’ citing a $1 billion peak market opportunity for Zusduri and revising valuation models accordingly.<a href="https://stocktwits.com/news-articles/markets/equity/urogen-price-target-upgrade-after-fda-approval-for-cancer-medicine/chli4GKRRbJ">Guggenheim and D. Boral</a> also reaffirmed bullish views on UroGen Pharma, calling the FDA's early approval of Zusduri a 'surprise decision' that bypassed further trial requirements and validated regulatory flexibility in high-unmet-need cancer settings.The drug, a combination of mitomycin and sterile hydrogel, is administered once weekly for six weeks via catheter, offering a non-surgical alternative to transurethral resection of bladder tumors, the current standard of care.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.The stock has risen 12.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

UroGen Pharma Stock Scores Bullish Price Target Revisions Up To $47 Following FDA Nod For Zusduri

UroGen Pharma shares rallied to a three-month high after the FDA approved Zusduri, a non-surgical treatment for a type of bladder cancer.

Equity

Shares of UroGen Pharma (URGN) shot up 9% on Friday morning after Guggenheim hiked its price target on the stock on the heels of the U.S. Food and Drug Administration approving its Zusduri medication.The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.urogen.com/news-releases/news-release-details/us-fda-approves-urogens-zusduritm-mitomycin-intravesical">approved</a> Zusduri for adults with a type of cancer of the lining of the bladder called recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG-IR-NMIBC) on Thursday. Zusduri consists of mitomycin and sterile hydrogel and is designed for potent tumor ablation.Patients can receive their Zusduri dose from a healthcare provider once a week for 6 weeks into the bladder through a urinary catheter, as opposed to the existing standard of care which is a surgical procedure called transurethral resection of bladder tumor.Guggenheim subsequently raised the firm's price target on UroGen Pharma to $30 from $15 while keeping a ‘Buy’ rating on the shares.The new price target implies a near 171% upside to the stock’s closing price of $11.08 on Thursday.The FDA approval for Zusduri, a day ahead of the deadline, is "a surprise decision" following the negative Oncologic Drug Advisory Committee (ODAC) vote during an FDA advisory committee meeting last month, the analyst told investors, as per TheFly.Last month, the ODAC committee narrowly voted against its benefit/risk profile, effectively ending hopes for approval as the FDA considers independent advice from the committee.The firm believes this outcome represents a best-case scenario for UroGen, given that the marketing approval indicates a broad indication of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, without the need to conduct another large randomized controlled trial and "only minor safety warnings."D. Boral Capital analyst Jason Kolbert, meanwhile, reiterated a ‘Buy’ rating and $25 price target on UroGen Pharma. The approval validates the FDA's willingness to exercise flexibility in high-unmet-need indications, despite divided advisory input, the analyst said.Zusduri is expected to be available in the U.S. on or around July 1, 2025, for the treatment of adults with recurrent LG-IR-NMIBC. LG-IR-NMIBC affects approximately 82,000 people in the U.S. each year, and of those, an estimated 59,000 are recurrent cases.On Stocktwits, retail sentiment around UroGen rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume increased from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1274/136;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_9_30_23_AM_png_01d194b268.webp" alt="URGN's Sentiment Meter and Message Volume as of 9:30 a.m. ET on Jun 13, 2025 | Source: Stocktwits" width="1274" height="136"><figcaption>URGN's Sentiment Meter and Message Volume as of 9:30 a.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism that the stock would reach $20.<stembedurl>https://stocktwits.com/TarriffKing007/message/617822498</stembedurl><a href="https://stocktwits.com/symbol/URGN">URGN stock</a> is up approximately 13% this year but down by 31% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-inks-5.3-billion-deal-with-cspc-pharma-for-new-drug-candidates/chli5sARRbG">AstraZeneca Inks $5.3B Deal With CSPC Pharma For Developing New Oral Drug Candidate, But Retail’s In No Mood To Cheer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

UroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20

The new price target of $30 implies a near 171% upside to the stock’s closing price of $11.08 on Thursday.

Shares of biotech company UroGen Pharma Ltd. (URGN) plummeted 48% on Wednesday noon after the company said that a committee of the U.S. Food and Drug Administration (FDA) voted in opposition to a favorable benefit-risk profile for its investigational drug UGN-102, an intravesical solution for the treatment of a recurrent form of bladder cancer.CEO Liz Barrett <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250521737507/en/UroGen-Announces-Outcome-of-Oncologic-Drugs-Advisory-Committee-for-UGN-102-for-the-Treatment-of-Recurrent-Low-Grade-Intermediate-Risk-Non-Muscle-Invasive-Bladder-Cancer-LG-IR-NMIBC">said</a> the company is "disappointed" by the outcome of the meeting of FDA’s Oncologic Drugs Advisory Committee (ODAC), but added that the company believes in the clinical data in support of the drug.Low-grade intermediate-risk nonmuscle-invasive bladder cancer has no FDA-approved therapies, the CEO said, while adding that it is looking forward to working with the FDA as they complete their review of its new drug application (NDA).The FDA considers independent advice from ODAC, which weighs down the possibility of approval. The FDA is expected to conclude its review of the application by June 13.UGN-102 for intravesical solution is an innovative drug formulation of mitomycin, an antibiotic used as a drug in cancer treatment. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.The company said the adverse impacts identified with the treatment in its late-stage trial, such as urine retention, are typically manageable in routine urologic practice. &nbsp;UroGen submitted its NDA to the FDA in August 2024. If approved in June, the company initially said it would make the product available in July.On Stocktwits, retail sentiment around UroGen remained unchanged within the ‘extremely bullish’ territory over the past 24 hours while message volume stayed put at ‘extremely high’ levels. &nbsp;<figure class="image"><img style="aspect-ratio:626/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_21_at_1_58_13_PM_png_0f90b9f92d.webp" alt="URGN's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 21, 2025 | Source: Stocktwits" width="626" height="65"><figcaption>URGN's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 21, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/URGN">URGN stock</a> is down by about 64% this year and nearly 71% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/shopify-bets-on-gen-ai-with-new-ai-tools-to-simplify-store-creation-but-stock-drops/ch0eOwYRbYo">Shopify Bets On Gen-AI With New AI Tools To Simplify Store Creation But Stock Drops</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

UroGen Stock Slumps After FDA Advisory Committee Flag Concerns On Its Investigational Drug: But Retail’s Unruffled

The Food and Drug Administration is expected to conclude its review of UroGen’s UGN-102 application by June 13.

UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will...

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced expansion of its...

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from the...

UroGen Pharma to Present at Upcoming Investor Conferences

ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the 3-month...

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

UroGen Pharma Ltd

Will Meta ($META) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Meta Platforms Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.69	--	--	N/A
Q2 '25	-$0.83	-$1.05	-25.91%	MISSED
Q1 '25	-$0.80	-$0.92	-15.10%	MISSED
Q4 '24	-$0.72	-$0.80	-11.16%	MISSED
Q3 '24	-$0.82	-$0.55	32.69%	BEAT

URGN
UroGen Pharma Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest URGN News

URGNUroGen Pharma Ltd